Parag Agarwal: No, so specific timelines, we’re not sharing Rahul. So, some of these products, we have filed, some of these products are under development. And obviously, the launch is linked to both IP scenario as well as we being able to secure the approval. So, while some of these should start coming to the market may be FY 2025, FY 2026 onwards, but that is what we believe. We do not have any firm timeline because all these are linked to both approval and IP.
Rahul Singh: Okay, sir. And this mid-single-digit growth, which you’re talking about the US portfolio on an ex-REVLIMID basis. So, that essentially will be driven by these 25, 30 launches, which we are talking about?
Erez Israeli: Again, I know you you’re putting with and without the product, we are not looking at in this way. By the time that the price of origins will come to this product, which will be naturally part of today’s. So, we are not looking at the market with and without. And absolutely these products that we mentioned will be part of the the growth in the United States and from time-to-time because of the nature of such a product we will see blinks that will be much more than the single-digit which we discussed. So, we are reiterating that we will see growth on the continuous basis, and from time-to-time we will see upside.
Rahul Singh: Sure sir. Thank you. That’s it for my side.
Operator: Thank you. Next question is on the line of Shyam Srinivasan from Goldman Sachs. Please go ahead.
Shyam Srinivasan: Yes, thank you for taking my question. Just the first one is on this recent launch by Amazon in the US for this RX pass. Right. So, they have started a subscription based in a $5 per month for the most common like 60 odd generic medicines. I know, it was launched only yesterday across the entire United States. But it isn’t team any early thoughts on you know, how the supply chain could potentially change? Given that if they start making meaningful progress is that — is the uninsured or the out-of-pocket population? Is it significant? You think, because it seemed doesn’t seem to include Medicaid, Medicare. So that’s one your initial thoughts just on the industry development.
Erez Israeli: So, initial, it’s definitely at the channel that was not there before and then there will be — and it will be impactful, I believe. And all the time, whatever is not covered, I believe will be covered. So, it supposes it’s likely to have and it will make the retail more competitive. And it will be dealt with opportunities as well as trips to for the industry. And so, we also saw this kind of stuff that is happening in other countries. But let’s say as initial so primarily, I see it as another channel that we can use.
Shyam Srinivasan: Got it. So, I now know that — we now know that Amazon doesn’t directly deal with manufacturers, they probably go through the existing supply chain. But it is do you foresee or have you seen examples globally, where you know, somebody like that directly deals with manufacturer, so you think those kinds of business models can’t evolve?
Erez Israeli: I believe this — wind will be also direct the interactions with the manufacturer.
Shyam Srinivasan: Got it. Thank you. And my second question just on some of the commentary around the SG&A. In your press release, you’ve talked about one of expenses in the SG&A both I think sequentially and y-or-y so what are these? And is it — if you could quantify or qualify please? Thank you.
